Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand?
Abstract Heart disease remains a leading cause of mortality and a major worldwide healthcare burden. Recent advances in stem cell biology have made it feasible to derive large quantities of cardiomyocytes for disease modeling, drug development, and regenerative medicine. The discoveries of reprogram...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2015-07-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.201504395 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849761452763643904 |
|---|---|
| author | Antje D Ebert Sebastian Diecke Ian Y Chen Joseph C Wu |
| author_facet | Antje D Ebert Sebastian Diecke Ian Y Chen Joseph C Wu |
| author_sort | Antje D Ebert |
| collection | DOAJ |
| description | Abstract Heart disease remains a leading cause of mortality and a major worldwide healthcare burden. Recent advances in stem cell biology have made it feasible to derive large quantities of cardiomyocytes for disease modeling, drug development, and regenerative medicine. The discoveries of reprogramming and transdifferentiation as novel biological processes have significantly contributed to this paradigm. This review surveys the means by which reprogramming and transdifferentiation can be employed to generate induced pluripotent stem cell‐derived cardiomyocytes (iPSC‐CMs) and induced cardiomyocytes (iCMs). The application of these patient‐specific cardiomyocytes for both in vitro disease modeling and in vivo therapies for various cardiovascular diseases will also be discussed. We propose that, with additional refinement, human disease‐specific cardiomyocytes will allow us to significantly advance the understanding of cardiovascular disease mechanisms and accelerate the development of novel therapeutic options. |
| format | Article |
| id | doaj-art-31e62052ac2e434da615c665df94e51d |
| institution | DOAJ |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2015-07-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-31e62052ac2e434da615c665df94e51d2025-08-20T03:06:01ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842015-07-01791090110310.15252/emmm.201504395Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand?Antje D Ebert0Sebastian Diecke1Ian Y Chen2Joseph C Wu3Stanford Cardiovascular Institute, Stanford University School of MedicineMax Delbrück CenterStanford Cardiovascular Institute, Stanford University School of MedicineStanford Cardiovascular Institute, Stanford University School of MedicineAbstract Heart disease remains a leading cause of mortality and a major worldwide healthcare burden. Recent advances in stem cell biology have made it feasible to derive large quantities of cardiomyocytes for disease modeling, drug development, and regenerative medicine. The discoveries of reprogramming and transdifferentiation as novel biological processes have significantly contributed to this paradigm. This review surveys the means by which reprogramming and transdifferentiation can be employed to generate induced pluripotent stem cell‐derived cardiomyocytes (iPSC‐CMs) and induced cardiomyocytes (iCMs). The application of these patient‐specific cardiomyocytes for both in vitro disease modeling and in vivo therapies for various cardiovascular diseases will also be discussed. We propose that, with additional refinement, human disease‐specific cardiomyocytes will allow us to significantly advance the understanding of cardiovascular disease mechanisms and accelerate the development of novel therapeutic options.https://doi.org/10.15252/emmm.201504395cardiomyocytesdisease modelinggenome editinghuman induced pluripotent stem cellstissue engineering |
| spellingShingle | Antje D Ebert Sebastian Diecke Ian Y Chen Joseph C Wu Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand? EMBO Molecular Medicine cardiomyocytes disease modeling genome editing human induced pluripotent stem cells tissue engineering |
| title | Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand? |
| title_full | Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand? |
| title_fullStr | Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand? |
| title_full_unstemmed | Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand? |
| title_short | Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand? |
| title_sort | reprogramming and transdifferentiation for cardiovascular development and regenerative medicine where do we stand |
| topic | cardiomyocytes disease modeling genome editing human induced pluripotent stem cells tissue engineering |
| url | https://doi.org/10.15252/emmm.201504395 |
| work_keys_str_mv | AT antjedebert reprogrammingandtransdifferentiationforcardiovasculardevelopmentandregenerativemedicinewheredowestand AT sebastiandiecke reprogrammingandtransdifferentiationforcardiovasculardevelopmentandregenerativemedicinewheredowestand AT ianychen reprogrammingandtransdifferentiationforcardiovasculardevelopmentandregenerativemedicinewheredowestand AT josephcwu reprogrammingandtransdifferentiationforcardiovasculardevelopmentandregenerativemedicinewheredowestand |